Lexicon Pharmaceuticals (LXRX) EBITDA Margin (2010 - 2026)
Lexicon Pharmaceuticals' (LXRX) quarterly EBITDA Margin came in at 4.72% in Q1 2026, up 203007.0% year-on-year from N/an in Q1 2025, and up 98.25% on a QoQ basis from 269.07% in Q4 2025.
Lexicon Pharmaceuticals (LXRX) EBITDA Margin (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 16 years of EBITDA Margin data on file, last reported at 4.72% in Q1 2026.
- On a quarterly basis, EBITDA Margin rose 203007.0% year-over-year to 4.72% in Q1 2026; TTM through Mar 2026 was 34.79%, a 53377.0% increase from a year earlier, with the FY2025 full-year figure at 98.21%, up 53600.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 4.72%, up from 269.07% in the prior quarter.
- Over the last five years, EBITDA Margin for LXRX reached as high as 12.94% in Q2 2025 and fell as low as 68591.43% in Q2 2022.
- Historically, EBITDA Margin has averaged 10321.92% across 5 years, with a median of 3360.9% in 2024.
- Across the five-year window, EBITDA Margin surged 5338868 bps in 2023 and slumped 14579 bps in 2025, its largest moves.
- Year by year, EBITDA Margin stood at 68591.43% in 2022, then jumped by 91 bps to 6101.44% in 2023, then soared by 98 bps to 123.28% in 2024, then slumped by 118 bps to 269.07% in 2025, then surged by 98 bps to 4.72% in 2026.
- Per Business Quant data, the three most recent EBITDA Margin figures were 4.72% in Q1 2026, 269.07% in Q4 2025, and 85.93% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lexicon Pharmaceuticals | 979.13 Mn | 808.47 Mn | 20.99 Mn | -4.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.72% |
| Dec 31, 2025 | -269.07% |
| Sep 30, 2025 | -85.93% |
| Jun 30, 2025 | 12.94% |
| Mar 31, 2025 | -2,034.79% |
| Dec 31, 2024 | -123.28% |
| Sep 30, 2024 | -3,639.60% |
| Jun 30, 2024 | -3,360.90% |
| Mar 31, 2024 | -4,147.58% |
| Dec 31, 2023 | -6,101.44% |
| Sep 30, 2023 | -30,636.42% |
| Jun 30, 2023 | -15,202.75% |
| Jun 30, 2022 | -68,591.43% |
| Dec 31, 2020 | -3,747.74% |
| Jun 30, 2020 | -258,316.00% |
| Mar 31, 2020 | -780.57% |
| Dec 31, 2019 | -541.05% |
| Sep 30, 2019 | 78.58% |
| Jun 30, 2019 | -2,156.40% |
| Mar 31, 2019 | -716.24% |